Diagnosis and treatment of hereditary angioedema: An expert opinion
10.4168/aard.2022.10.2.80
- Author:
Jae-Woo JUNG
1
;
So-Young PARK
;
Sun Young YOON
;
Gun-Woo KIM
;
Kyoung-Hee SOHN
;
Sung-Yoon KANG
;
Hye Jung PARK
;
Min-Kyu KANG
;
Joo-Hee KIM
;
Kyung Hee PARK
;
Dong In SUH
;
Dong Hun LEE
;
Sae-Hoon KIM
;
Hyouk-Soo KWON
;
Hye-Ryun KANG
Author Information
1. Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
- Publication Type:REVIEW
- From:Allergy, Asthma & Respiratory Disease
2022;10(2):80-88
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hereditary angioedema (HAE) is a rare disease, but it severely interrupts daily life activities and can sometimes be life-threatening. Therefore, early diagnosis and prompt treatment of HAE attacks are critical. Physicians should be aware of how to diagnose and manage HAE to prepare not to miss a diagnosis when treating HAE patients. Physicians must also carry out tests to confirm the diagnosis of HAEs caused by C1 inhibitor deficiency (type 1) or C1 inhibitor dysfunction (type 2) in patients with recurrent angioedema. In addition, recent studies revealed another type of HAE which is not related to C1 inhibitor (normal C1 inhibitor HAE). Once HAE is confirmed, patients and their caregivers should be given with short-term and long-term treatment plans to relieve or prevent HAE attacks. HAE requires life-long measures, including psychological support for patients and self-management education.
